Guest guest Posted December 21, 2010 Report Share Posted December 21, 2010 Genzyme has rebranded Campath for the multiple sclerosis market according to BNET. Genzyme wants to substantially increase the price of Lemtrada, but they have problems then with the costs of Campath used for CLL. One option proposed is to offer Campath free of charge to CLL patients, which would open up the MS market up to much higher prices. How this will actually pan out is still unknown...stay tuned! Source BNET : http://tinyurl.com/2b3bzdd ~chris Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.